Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
OMICS A Journal of Integrative Biology(2)
Biomedical Reports(1)
Current Pharmaceutical Biotechnology(1)
Drug Metabolism and Drug Interactions(1)
Drug Metabolism and Personalized Therapy(1)
Área temáticas
Farmacología y terapéutica(5)
Enfermedades(2)
Dirección general(1)
Fisiología humana(1)
Grupos de personas(1)
Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusCYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
ArticleAbstract: Global precision medicine demands characterization of drug metabolism and phenotype variation in divPalabras claves:Biomarkers, developing world omics, drug metabolism variation, global personalized medicine, Systems DiagnosticsAutores:Adrián LLerena, de Andrés F., Naranjo M.E.G., Ramos B., Sosa-Macías M.G.Fuentes:scopusFrequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
ArticleAbstract: The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed suPalabras claves:Cytochrome P450 2C9, DIABÉTES, Glibenclamide, Glycated hemoglobin A1c, MetforminAutores:Adrián LLerena, Castillo-Nájera F., Cuautle-Rodríguez P., de Andrés F., Molina-Guarneros J.A., Rodríguez-Rivera N.S.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusHigh-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients
ArticleAbstract: Background: Aripiprazole (ARI) is an antipsychotic drug that is metabolized to dehydroaripiprazole (Palabras claves:Aripiprazole, CYP2D6, Dehydroaripiprazole, High-performance liquid chromatography, Psychiatric patientsAutores:Adrián LLerena, de Andrés F., De la Rubia A., Dorado P., Gonz Ález A., Gonz Ález I., Naranjo M.E.G., Peñ As-Lledó E.Fuentes:scopusLessons from Cuba for global precision medicine: CYP2D6 genotype is not a robust pbkp_redictor of CYP2D6 ultrarapid metabolism
ArticleAbstract: A long-standing question and dilemma in precision medicine is whether and to what extent genotypingPalabras claves:Biomarkers, developing world omics, Diagnostic Medicine, Innovation Systems, personalized medicine, system diagnosticsAutores:Adrián LLerena, Calzadilla L.R., de Andrés F., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusSimultaneous determination of cytochrome P450 oxidation capacity in humans: A review on the phenotyping cocktail approach
ReviewAbstract: Intra-and/or inter-individual variability in drug response is mainly a result of either subtherapeutPalabras claves:Cocktail, Cytochrome p450, drug metabolism, In vivo, Phenotype, Probe drug, SelectiveAutores:Adrián LLerena, de Andrés F.Fuentes:scopusTo Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population
ArticleAbstract: Genetic variations within the cytochrome P450 (CYP450) superfamily of drug metabolizing enzymes confPalabras claves:Biomarkers, developing world omics, Diagnostic Medicine, Innovation Systems, personalized medicine, Systems DiagnosticsAutores:Adrián LLerena, de Andrés F., Enrique Terán, Francisco J.López Hernández, Santiago TeránFuentes:googlescopus